Avicanna Inc (TO:AVCN) — Market Cap & Net Worth
Market Cap & Net Worth: Avicanna Inc (AVCN)
Avicanna Inc (TO:AVCN) has a market capitalization of $12.74 Million (CA$17.61 Million) as of June 17, 2026. Listed on the TO stock exchange, this Canada-based company holds position #26455 globally and #1079 in its home market, demonstrating a 21.74% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Avicanna Inc's stock price CA$0.14 by its total outstanding shares 125791870 (125.79 Million). Review Avicanna Inc total liabilities to assess the company's total debt and financial obligations.
Avicanna Inc Market Cap History: 2019 to 2026
Avicanna Inc's market capitalization history from 2019 to 2026. Data shows change from $231.13 Million to $12.74 Million (-42.24% CAGR).
Avicanna Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Avicanna Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
0.80x
Avicanna Inc's market cap is 0.80 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2019 | $231.13 Million | $168.25K | -$22.21 Million | 1373.71x | N/A |
| 2020 | $119.20 Million | $1.57 Million | -$32.86 Million | 75.93x | N/A |
| 2021 | $70.98 Million | $3.27 Million | -$16.77 Million | 21.71x | N/A |
| 2022 | $37.31 Million | $4.05 Million | -$14.73 Million | 9.22x | N/A |
| 2023 | $31.85 Million | $16.79 Million | -$8.74 Million | 1.90x | N/A |
| 2024 | $27.75 Million | $25.46 Million | -$3.62 Million | 1.09x | N/A |
| 2025 | $20.47 Million | $25.48 Million | -$2.84 Million | 0.80x | N/A |
Competitor Companies of AVCN by Market Capitalization
Companies near Avicanna Inc in the global market cap rankings as of June 17, 2026.
Key companies related to Avicanna Inc by market ranking:
- Takeda Pharmaceutical Co Ltd ADR (NYSE:TAK): Ranked #512 globally with a market cap of $52.60 Billion USD.
- GALDERMA GROUP AG (NYSE:GALDY): Ranked #560 globally with a market cap of $48.78 Billion USD.
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #613 globally with a market cap of $44.69 Billion USD ( CN¥305.43 Billion CNY).
- Takeda Pharmaceutical Company Limited (F:TKDA): Ranked #629 globally with a market cap of $43.60 Billion USD ( €37.29 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #512 | Takeda Pharmaceutical Co Ltd ADR | NYSE:TAK | $52.60 Billion | $16.65 |
| #560 | GALDERMA GROUP AG | NYSE:GALDY | $48.78 Billion | $43.41 |
| #613 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $44.69 Billion | CN¥47.88 |
| #629 | Takeda Pharmaceutical Company Limited | F:TKDA | $43.60 Billion | €13.60 |
Avicanna Inc Historical Marketcap From 2019 to 2026
Between 2019 and today, Avicanna Inc's market cap moved from $231.13 Million to $ 12.74 Million, with a yearly change of -42.24%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | CA$12.74 Million | -37.78% |
| 2025 | CA$20.47 Million | -26.23% |
| 2024 | CA$27.75 Million | -12.86% |
| 2023 | CA$31.85 Million | -14.63% |
| 2022 | CA$37.31 Million | -47.44% |
| 2021 | CA$70.98 Million | -40.46% |
| 2020 | CA$119.20 Million | -48.43% |
| 2019 | CA$231.13 Million | -- |
End of Day Market Cap According to Different Sources
On Jun 16th, 2026 the market cap of Avicanna Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $12.74 Million USD |
| MoneyControl | $12.74 Million USD |
| MarketWatch | $12.74 Million USD |
| marketcap.company | $12.74 Million USD |
| Reuters | $12.74 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Avicanna Inc
Avicanna Inc., a commercial-stage biopharmaceutical company, engages in the research, development, advancement, and commercialization of evidence-based cannabinoid-based products and formulations for medical and pharmaceutical markets in Canada and internationally. It provides medical cannabis formulary products, including oral, sublingual, topical, and transdermal deliveries with various ratios … Read more